PSA response following the ‘steroid switch’ in patients with castration‑resistant prostate cancer treated with abiraterone: A case report

Kato,Tomonori; Kojima,Satoko; Fujimoto,Ayumi; Otsuka,Kotaro; Suyama,Takahito; Hou,Kyokushin; Araki,Kazuhiro; Masuda,Hiroshi; Yamazaki,Kazuto; Komiya,Akira; Naya,Yukio

doi:10.3892/ol.2018.9321

PSA response following the ‘steroid switch’ in patients with castration‑resistant prostate cancer treated with abiraterone: A case report

Authors:
- Tomonori Kato
- Satoko Kojima
- Ayumi Fujimoto
- Kotaro Otsuka
- Takahito Suyama
- Kyokushin Hou
- Kazuhiro Araki
- Hiroshi Masuda
- Kazuto Yamazaki
- Akira Komiya
- Yukio Naya
View Affiliations

Affiliations: Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299‑0111, Japan, Department of Pathology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299‑0111, Japan, Department of Urology, Chiba University Graduate School of Medicine, Chiba, Chiba 260‑8677, Japan
Published online on: August 17, 2018 https://doi.org/10.3892/ol.2018.9321
Pages: 5383-5388

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A 69‑year‑old man presented initially with back pain and incomplete bilateral lower limb paralysis. The level of prostate‑specific antigen (PSA) in the patient was elevated to 167.0 ng/ml, and multiple bone metastases were detected. Thoracic laminectomy was performed in an emergency due to spinal decompression. Subsequently, the patient was diagnosed with prostate cancer from an examination of resected bone specimens. Combined androgen blockade with degarelix and bicalutamide was initiated in October 2013. Consequently, the serum PSA level decreased to <1.0 ng/ml, but thereafter gradually increased. Subsequent bicalutamide withdrawal response was not observed, and switch of anti‑androgen therapy to flutamide also resulted in a poor response. Then, abiraterone (1,000 mg daily) in combination with prednisolone (10 mg daily) was initiated when the level of PSA increased to 35.9 ng/ml in June 2015. The level of PSA decreased to the lowest point of 4 ng/ml; however, PSA level increased again to 21.7 ng/ml in April 2016. Consequently, a ‘steroid switch’ was attempted. Abiraterone therapy was continued, but concomitant corticosteroid was switched from prednisone to dexamethasone (1.0 mg per day). Fortunately, serum PSA level decreased promptly to the lowest point of 0.6 ng/ml. In the present case report, a review of recent literature was presented and potential explanations of the mechanism underlying the ‘steroid switch’ were described. Pharmacokinetic differences between dexamethasone and prednisolone may partially explain why the ‘steroid switch’ occurs. Other mechanisms may include the activation of the glucocorticoid receptor, mineralocorticoid receptor and/or mutant androgen receptor. Corticosteroids accelerate a number of transcription factors, cellular growth factors and cytokines, which may also be potential mechanisms. The ‘steroid switch’ at PSA progression might be a feasible option for therapy, which may delay the development of the disease. Although the underlying mechanisms require further study, clinicians should pay attention to this phenomenon.

View Figures

View References

1	de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. 2011. View Article : Google Scholar : PubMed/NCBI
2	Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
3	James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, et al: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet. 387:1163–1177. 2016. View Article : Google Scholar : PubMed/NCBI
4	Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, et al: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 377:352–360. 2017. View Article : Google Scholar : PubMed/NCBI
5	Leppert W and Buss T: The role of corticosteroids in the treatment of pain in cancer patients. Curr Pain Headache Rep. 16:307–313. 2012. View Article : Google Scholar : PubMed/NCBI
6	Khandwala HM, Vassilopoulou-Sellin R, Logethetis CJ and Friend KE: Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract. 7:11–15. 2001. View Article : Google Scholar : PubMed/NCBI
7	Eichholz A, Ferraldeschi R, Attard G and de Bono JS: Putting the brakes on continued androgen receptor signaling in castration resistant prostate cancer. Mol Cell Endocrinol. 360:68–75. 2012. View Article : Google Scholar : PubMed/NCBI
8	Komiya A, Shimbo M, Suzuki H, Imamoto T, Kato T, Fukasawa S, Kamiya N, Naya Y, Mori I and Ichikawa T: Oral low-dose dexamethasone for androgen-independent prostate cancer patients. Oncol Lett. 1:73–79. 2010. View Article : Google Scholar : PubMed/NCBI
9	Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J and Parker C: A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol. 67:673–679. 2015. View Article : Google Scholar : PubMed/NCBI
10	Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, et al: Tumour responses following a steroid switch from prednisone to dexamethasone in castration resistant prostate cancer patients progressing on abiraterone. Br J Cancer. 111:2248–2253. 2014. View Article : Google Scholar : PubMed/NCBI
11	Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp NJ and Gillessen S: Abiraterone-what is wrong with the adrenal glands? Clin Genitourin Cancer. 12:e133–e137. 2014. View Article : Google Scholar : PubMed/NCBI
12	Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L and Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 7:590–597. 1989. View Article : Google Scholar : PubMed/NCBI
13	Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP and Parker CC: Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int. 101:440–443. 2008.PubMed/NCBI
14	De Santis M and Saad F: Practical guidance on the role of corticosteroids in the treatment of metastatic castration resistant prostate cancer. Urology. 96:156–164. 2016. View Article : Google Scholar : PubMed/NCBI
15	Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, et al: Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol. 163:834–837. 2000. View Article : Google Scholar : PubMed/NCBI
16	Diederich S, Scholz T, Eigendorff E, Bumke-Vogt Ch, Quinkler M, Exner P, Pfeiffer AF, Oelkers W and Bähr V: Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: Receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases. Horm Metab Res. 36:423–429. 2004. View Article : Google Scholar : PubMed/NCBI
17	Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T and Okuyama A: Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 89:2570–2576. 2000. View Article : Google Scholar : PubMed/NCBI
18	Crona DJ and Whang YE: Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 9(pii): E672017. View Article : Google Scholar : PubMed/NCBI
19	Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, et al: Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155:1309–1322. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lan NC, Graham B, Bartter FC and Baxter JD: Binding of steroids to mineralocorticoid receptors: Implications for in vivo occupancy by glucocorticoids. J Clin Endocrinol Metab. 54:332–342. 1982. View Article : Google Scholar : PubMed/NCBI
21	Dovio A, Sartori ML, De Francia S, Mussino S, Perotti P, Saba L, Abbadessa G, Racca S and Angeli A: Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. J Steroid Biochem Mol Biol. 116:29–36. 2009. View Article : Google Scholar : PubMed/NCBI
22	Leach DA, Powell SM and Bevan CL: Women in Cancer Thematic Review: New roles for nuclear receptors in prostate cancer. Endocr Relat Cancer. 23:T85–T108. 2016. View Article : Google Scholar : PubMed/NCBI
23	Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN and Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 332:1393–1398. 1995. View Article : Google Scholar : PubMed/NCBI
24	Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM and Feldman D: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 6:703–706. 2000. View Article : Google Scholar : PubMed/NCBI
25	Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, et al: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 72:2176–2182. 2012. View Article : Google Scholar : PubMed/NCBI
26	Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, et al: Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst. 93:1739–1746. 2001. View Article : Google Scholar : PubMed/NCBI
27	Lam JS, Leppert JT, Vemulapalli SN, Shvarts O and Belldegrun AS: Secondary hormonal therapy for advanced prostate cancer. J Urol. 175:27–34. 2006. View Article : Google Scholar : PubMed/NCBI
28	Yano A, Fujii Y, Iwai A, Kageyama Y and Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 12:3003–3009. 2006. View Article : Google Scholar : PubMed/NCBI
29	Akakura K, Suzuki H, Ueda T, Komiya A, Ichikawa T, Igarashi T and Ito H: Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin-6. Prostate. 56:106–109. 2003. View Article : Google Scholar : PubMed/NCBI
30	Ueda T, Bruchovsky N and Sadar MD: Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 277:7076–7085. 2002. View Article : Google Scholar : PubMed/NCBI